Edgewise Therapeutics Inc [EWTX] stock is trading at $13.93, up 0.65%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EWTX shares have gain 10.47% over the last week, with a monthly amount drifted -11.56%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on June 30, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $42. Previously, Guggenheim started tracking the stock with Buy rating on April 30, 2025, and set its price target to $41. On April 02, 2025, downgrade downgraded it’s rating to Sector Perform but maintained its price target of $14 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $50 on March 07, 2025. Stifel initiated its recommendation with a Hold and recommended $30 as its price target on January 22, 2025. Evercore ISI started tracking with a Outperform rating for this stock on November 22, 2024, and assigned it a price target of $45. In a note dated March 07, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $48 on this stock.
Edgewise Therapeutics Inc [EWTX] stock has fluctuated between $10.60 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $13.93 at the most recent close of the market. An investor can expect a potential return of 258.94% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.31 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.72 points at the first support level, and at 13.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.16, and for the 2nd resistance point, it is at 14.38.
Ratios To Look Out For
For context, Edgewise Therapeutics Inc’s Current Ratio is 20.99. Further, the Quick Ratio stands at 20.99, while the Cash Ratio is 2.36.
Transactions by insiders
Recent insider trading involved Russell Alan J, Chief Scientific Officer, that happened on May 02 ’25 when 1551.0 shares were sold. General Counsel, MOORE JOHN R completed a deal on May 02 ’25 to sell 1930.0 shares. Meanwhile, President and CEO KOCH KEVIN sold 4276.0 shares on May 02 ’25.
